Journals / Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi / 2020 / Cilt: 25 - Sayı: 3

Factors Related to Mortality in Carbapenem Resistant Acinetobacter baumannii Infections in Intensive Care Units: A Prospective Observational Study

Yoğun Bakımda Gelişen Karbapeneme Dirençli Acinetobacter baumannii İnfeksiyonlarında Mortalite ile İlişkili Faktörler: Prospektif Gözlem Çalışması

Pages
391–400
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We suggest that prompt administration of the proper antibiotic treatment to the patients who have risk factors for carbapenem-resistant A. baumannii infection can contribute to survival.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: Management of carbapenem resistant Acinetobacter baumannii infections in intensive care units is challenging because of few treatment options and poor outcomes.
📊
Key Findings & Data:Materials and Methods: In the 6-month study period, we included 60 patients with carbapenem resistant A. baumannii infections (45 ventilator associated pneumonia and 15 bacteremia) in two intensive care units of our hospital.
💡
Conclusion & Impact:We suggest that prompt administration of the proper antibiotic treatment to the patients who have risk factors for carbapenem-resistant A. baumannii infection can contribute to survival.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Introduction: Management of carbapenem resistant Acinetobacter baumannii infections in intensive care units is challenging because of few treatment options and poor outcomes. In order to contribute to patients’ survival, the factors related to mortality in these infections were evaluated in this study. Materials and Methods: In the 6-month study period, we included 60 patients with carbapenem resistant A. baumannii infections (45 ventilator associated pneumonia and 15 bacteremia) in two intensive care units of our hospital. We collected data of the patients prospectively. We noted demographic features of patients, Acute Physiology and Chronic Health Evaluation (APACHE II) , Sequential Organ Failure Assessment (SOFA), Clinical Pulmonary Infection Score (CPIS), Acute Kidney Injury (AKIN) scores, antibiotic treatments, clinical and microbiological outputs, and mortality rates during treatment and on the 30th day. Results: We observed that infections appeared at mean 11th day of the patients’ stay in the intensive care unit. Carbapenem resistant A. baumannii isolates were highly resistant to antibiotics except colistin. Only 9% of the patients had proper empirical treatment. Twenty five percent of the patients were dead before having a specific antibiotic treatment. Crude mortality rate was 66.7%, and 30th day mortality was 71.7%. The patients who had colistin and tigecycline combination had higher survival rates, but it was statistically insignificant. In univariate analysis high SOFA score (p= 0.0001), high procalcitonin level (p= 0.01), septic shock (p= 0.005), renal insufficiency (p= 0.005), rheumatological disease (p= 0.03) were related to higher mortality. We detected high SOFA score on the first day of infection as the only mortality related factor in multivariate analysis (p= 0.012). The patients who had higher mortality were those with delayed (> 3 days) proper antimicrobial treatment (p= 0.03). Conclusion: In our study, the high SOFA score on the first day of infection in intensive care units was found as a risk factor for mortality. We suggest that prompt administration of the proper antibiotic treatment to the patients who have risk factors for carbapenem-resistant A. baumannii infection can contribute to survival.

Özet

Giriş: Yoğun bakımda gelişen karbapeneme dirençli Acinetobacter baumannii infeksiyonlarının yönetimi, tedavi seçeneklerinin az olmasıve kliniğinin kötü seyretmesi nedeniyle zorludur. Çalışmamızda, bu infeksiyonların seyrinde mortalite ile ilişkili faktörler değerlendirilmiştir. Sonuçların sağkalıma katkıda bulunması amaçlanmıştır.Materyal ve Metod: Altı aylık çalışma süresinde yoğun bakım ünitelerinde karbapeneme dirençli A. baumannii infeksiyonu olan 60 hasta(45 ventilatör ilişkili pnömoni ve 15 bakteremi) çalışmaya alındı. Hasta verileri prospektif olarak toplandı. Hastaların APACHE II (AkutFizyolojik ve Kronik Sağlık Değerlendirmesi), SOFA (Ardışık Organ Disfonksiyonu Değerlendirmesi), CPIS (Klinik Pulmoner İnfeksiyon Skoru)ve AKIN (Akut Böbrek Hasarı) skorları, antibiyotik tedavileri, takipteki klinik ve mikrobiyolojik yanıtları, tedavi sırasında ve 30. gündekimortalite oranları kaydedildi.Bulgular: İnfeksiyonların yoğun bakım yatışının ortalama 11. gününde geliştiği gözlendi. Kolistin dışındaki tüm antibiyotiklere karşı yüksek oranda direnç saptandı. Hastaların ancak %9’u uygun ampirik antibiyotik tedavisi aldı. Hastaların %25’i uygun antibiyotik tedavisibaşlanamadan kaybedildi. Kaba mortalite %66.7 ve 30. gündeki mortalite %71.7 olarak saptandı. Kolistin ve tigesiklin kombinasyonualan hastaların sağkalımı daha yüksek olmasına rağmen, fark istatistiksel olarak anlamlı değildi. Tek değişkenli analizde mortaliteyietkileyen faktörler; yüksek SOFA skoru (p= 0.0001), yüksek prokalsitonin değeri (p= 0.01), septik şok (p= 0.005), böbrek yetmezliği(p= 0.005) ve romatolojik hastalık olması (p= 0.03) olarak saptandı. Çok değişkenli analizde ise infeksiyonun birinci günündeki SOFAskoru mortalite ile ilişkili olarak tespit edildi (p= 0.012). Uygun antibiyotik tedavisi (> 3 gün) geç başlanan alan hastalarda mortalitedaha yüksekti (p= 0.03).Sonuç: Çalışmamızda yoğun bakımda infeksiyonun ilk gününde SOFA skoru mortalite için risk faktörü olarak saptanmıştır. Karbapenemdirençli A. baumannii infeksiyonu açısından risk faktörü olan olgularda ivedilikle uygun ampirik tedavinin başlanması ile sağkalımınarttırılabileceği düşünülmektedir.

🔖

Cite This Article

ZEKA, A. N., ARDA, B., SİPAHİ, O. R., UYAR, M. (2020). Factors Related to Mortality in Carbapenem Resistant Acinetobacter baumannii Infections in Intensive Care Units: A Prospective Observational Study. Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi, Cilt: 25 - Sayı: 3, 391–400. https://ajindex.com/articles/348070

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Mohd Sazlly Lim S, Zainal Abidin A, Liew SM, Roberts JA, Sime FB. The global prevalence of multidrug-resistance among Acinetobacter baumannii causing hospital-acquired and ventilator-associated pneumonia and its associated mortality: a systematic review and meta-analysis. J Infect 2019;79:593-600
  2. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. Discovery, research and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis 2018;18:318-27
  3. Isler B, Doi Y, Bonomo RA, Paterson DL. New treatment options against carbapenem-resistant Acinetobacter baumannii infections. Antimicrob Agents Chemother 2018;63:1110-8
  4. Doi Y. Treatment options for carbapenem-resistant gram-negative bacterial infections. Clin Infect Dis 2019;69(Suppl. 7):565-75
  5. Butler DA, Biagi M, Tan X, Qasmieh S, Bulman ZP, Wenzler E. Multidrug resistant Acinetobacter baumannii: resistance by any other name would still be hard to treat. Curr Infect Dis Rep 2019;21:46
  6. Tasbakan MS, Pullukcu H, Sipahi OR, Tasbakan MI, Aydemir S, Bacakoglu FJ. Is tigecyclin a good choice in the treatment of multidrug-resistant Acinetobacter baumannii pneumonia? J Chemother 2011;23:345-9
  7. Metan G, Sariguzel F, Sumerkan B. Facto rs influencing survival in patients with multi-drug-resistant Acinetobacter bacteraemia. Eur J Intern Med 2009;20:540-4
  8. Özgür ES, Horasan ES, Karaca K, Ersöz G, Naycı Atış S, Kaya A. Ventilator-associated pneumonia due to extensive drug-resistant Acinetobacter baumannii: risk factors, clinical features, and outcomes. Am J Infect Control 2014;42:206-8
  9. Kofteridis DP, Andrianaki AM, Maraki S, Mathioudaki A, Plataki M, Alexopoulou C, et al. Treatment pattern, prognostic factors, and outcome in patients with infection due to pan-drug-resistant gram-negative bacteria. Eur J Clin Microbiol Infect Dis 2020;39:965-70
  10. American Thoracic Society; infectious diseases society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416
  11. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections. Am J Infect Control 1988;16:128-40
  12. CLSI. Performance standards for antimicrobial susceptibility testing, M100-S22. 20th ed. Wayne: Clinical and Laboratory Standards Institute, 2012
  13. Boral B, Unaldi Ö, Ergin A, Durmaz R, Eser Ö